Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

101. A pharmacogenetic versus a clinical algorithm for warfarin dosing. Full Text available with Trip Pro

A pharmacogenetic versus a clinical algorithm for warfarin dosing. The clinical utility of genotype-guided (pharmacogenetically based) dosing of warfarin has been tested only in small clinical trials or observational studies, with equivocal results.We randomly assigned 1015 patients to receive doses of warfarin during the first 5 days of therapy that were determined according to a dosing algorithm that included both clinical variables and genotype data or to one that included clinical variables (...) only. All patients and clinicians were unaware of the dose of warfarin during the first 4 weeks of therapy. The primary outcome was the percentage of time that the international normalized ratio (INR) was in the therapeutic range from day 4 or 5 through day 28 of therapy.At 4 weeks, the mean percentage of time in the therapeutic range was 45.2% in the genotype-guided group and 45.4% in the clinically guided group (adjusted mean difference, [genotype-guided group minus clinically guided group], -0.2

2013 NEJM Controlled trial quality: predicted high

102. A randomized trial of genotype-guided dosing of warfarin. Full Text available with Trip Pro

A randomized trial of genotype-guided dosing of warfarin. The level of anticoagulation in response to a fixed-dose regimen of warfarin is difficult to predict during the initiation of therapy. We prospectively compared the effect of genotype-guided dosing with that of standard dosing on anticoagulation control in patients starting warfarin therapy.We conducted a multicenter, randomized, controlled trial involving patients with atrial fibrillation or venous thromboembolism. Genotyping for CYP2C9 (...) *2, CYP2C9*3, and VKORC1 (-1639G→A) was performed with the use of a point-of-care test. For patients assigned to the genotype-guided group, warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days. Patients in the control (standard dosing) group received a 3-day loading-dose regimen. After the initiation period, the treatment of all patients was managed according to routine clinical practice. The primary outcome measure was the percentage of time

2013 NEJM Controlled trial quality: predicted high

103. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 NHS Economic Evaluation Database.

104. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. Full Text available with Trip Pro

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. Dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of dabigatran in patients with mechanical heart valves.In this phase 2 dose-validation study, we studied two populations of patients: those who had undergone aortic- or mitral-valve replacement within the past 7 days and those who had undergone (...) such replacement at least 3 months earlier. Patients were randomly assigned in a 2:1 ratio to receive either dabigatran or warfarin. The selection of the initial dabigatran dose (150, 220, or 300 mg twice daily) was based on kidney function. Doses were adjusted to obtain a trough plasma level of at least 50 ng per milliliter. The warfarin dose was adjusted to obtain an international normalized ratio of 2 to 3 or 2.5 to 3.5 on the basis of thromboembolic risk. The primary end point was the trough plasma level

2013 NEJM Controlled trial quality: uncertain

105. Randomised controlled trial: Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes

Randomised controlled trial: Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar cardiovascular outcomes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Thromboprophylaxis in heart failure patients with sinus rhythm: aspirin and warfarin lead to similar

2013 Evidence-Based Medicine

106. Apixaban reduced stroke or systemic embolism more than warfarin in AF regardless of renal function. (Abstract)

Apixaban reduced stroke or systemic embolism more than warfarin in AF regardless of renal function. 23247956 2013 04 12 2012 12 18 1539-3704 157 12 2012 Dec 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Apixaban reduced stroke or systemic embolism more than warfarin in AF regardless of renal function. JC6-7 10.7326/0003-4819-157-12-201212180-02007 Jones Melvyn M MM University College London Medical School, London, England, UK. eng Comment Journal Article United States Ann

2012 Annals of Internal Medicine

107. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis Full Text available with Trip Pro

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis Animal and human studies support the importance of the coagulation cascade in pulmonary fibrosis.In a cohort of subjects with progressive idiopathic pulmonary fibrosis (IPF), we tested the hypothesis that treatment with warfarin at recognized therapeutic doses would reduce rates of mortality, hospitalization, and declines in FVC.This was a double-blind, randomized, placebo-controlled trial of warfarin targeting (...) an international normalized ratio of 2.0 to 3.0 in patients with IPF. Subjects were randomized in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 weeks. International normalized ratios were monitored using encrypted home point-of-care devices that allowed blinding of study therapy.The primary outcome measure was the composite outcome of time to death, hospitalization (nonbleeding, nonelective), or a 10% or greater absolute decline in FVC. Due to a low probability of benefit

2012 EvidenceUpdates Controlled trial quality: predicted high

108. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review

Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

109. Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism

Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism Management Briefs Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Briefs Management eBriefs: Provide VA senior managers with results from VA Health Services Research in a concise

2012 Veterans Affairs - R&D

110. Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis

Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

111. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. Full Text available with Trip Pro

Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. The need for anticoagulation after surgical aortic valve replacement (AVR) with biological prostheses is not well examined.To perform a nationwide study of the association of warfarin treatment with the risk of thromboembolic complications, bleeding incidents, and cardiovascular deaths after bioprosthetic AVR surgery.Through a search (...) in the Danish National Patient Registry, 4075 patients were identified who had bioprosthetic AVR surgery performed between January 1, 1997, and December 31, 2009. Concomitant comorbidity and medication were retrieved. Poisson regression models were used to determine risk.Incidence rate ratios (IRRs) of strokes, thromboembolic events, cardiovascular deaths, and bleeding incidents by discontinuing warfarin as opposed to continued treatment 30 to 89 days, 90 to 179 days, 180 to 364 days, 365 to 729 days

2012 JAMA

112. Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial (Abstract)

Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial To evaluate the impact of a pharmacist-led warfarin patient self-management program on quality of life and anticoagulation control compared with management in a physician-led specialized anticoagulation clinic.Prospective, randomized, controlled, open-label trial.Tertiary care academic medical center.A total of 114 patients aged 18-75 years who were followed (...) at a specialized anticoagulation clinic, had received warfarin for at least 6 months, and were expected to continue warfarin for a minimum of 4 months.All patients attended an educational session on anticoagulation provided by a pharmacist. Patients randomized to the self-management group (58 patients) also received practical training to use the CoaguChek XS device and a self-management dosing algorithm. Patients in the control group (56 patients) continued to undergo standard management at the anticoagulation

2012 EvidenceUpdates Controlled trial quality: uncertain

113. Review: New oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. (Abstract)

Review: New oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. 22986394 2012 12 03 2012 09 18 1539-3704 157 6 2012 Sep 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Review: new oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. JC3-2 10.7326/0003-4819-157-6-201209180-02002 Klein Liviu L eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 Am J Cardiol. 2012 Aug 1;110(3):453-60

2012 Annals of Internal Medicine

114. Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. (Abstract)

Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. 22910961 2012 10 19 2012 08 22 1539-3704 157 4 2012 Aug 21 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. JC2-7 10.7326/0003-4819-157-4-201208210-02007 Ahmad Tariq T Duke University School of Medicine, Durham, North Carolina, USA. Felker G Michael GM eng Comment Journal Article United States Ann

2012 Annals of Internal Medicine

115. INR Online Software for the Management of Warfarin Dosing in Patients Requiring Warfarin Treatment: Clinical Evidence

INR Online Software for the Management of Warfarin Dosing in Patients Requiring Warfarin Treatment: Clinical Evidence Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within (...) for the Management of Warfarin Dosing in Patients Requiring Warfarin Treatment: Clinical Evidence DATE: 8 August 2012 RESEARCH QUESTION What is the clinical evidence regarding the use of the INR Online Software, in conjunction with point of care testing, for the management of international normalized ratio dosing in patients requiring warfarin treatment? KEY MESSAGE No relevant information was identified regarding the INR Online Software, in conjunction with point of care testing, for the management

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

116. Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial Full Text available with Trip Pro

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required.The current analysis was undertaken to compare the periprocedural bleeding risk of patients in the Randomized (...) Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial treated with dabigatran and warfarin. Bleeding rates were evaluated from 7 days before until 30 days after invasive procedures, considering only the first procedure for each patient. A total of 4591 patients underwent at least 1 invasive procedure: 24.7% of patients received dabigatran 110 mg, 25.4% received dabigatran 150 mg, and 25.9% received warfarin, P=0.34. Procedures included: pacemaker/defibrillator insertion (10.3%), dental procedures

2012 EvidenceUpdates Controlled trial quality: uncertain

117. Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism

Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism Evidence-based Synthesis Program Department of Veterans Affairs Health Services Research & Development Service April 2012 Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism Prepared for: Department of Veterans Affairs Veterans Health Administration (...) . Warfarin and Newer Oral Anticoagulants: Long-term Prevention and Treatment of Arterial and VTE Evidence-based Synthesis Program PREFACE Quality Enhancement Research Initiative’s (QUERI’s) Evidence-based Synthesis Program (ESP) was established to provide timely and accurate syntheses of targeted healthcare topics of particular importance to Veterans Affairs (V A) managers and policymakers, as they work to improve the health and healthcare of Veterans. The ESP disseminates these reports throughout V

2012 Veterans Affairs Evidence-based Synthesis Program Reports

118. Warfarin in Heart Failure. (Abstract)

Warfarin in Heart Failure. 22551103 2012 05 24 2018 12 01 1533-4406 366 20 2012 May 17 The New England journal of medicine N. Engl. J. Med. Warfarin in heart failure. 1936-8 10.1056/NEJMe1202504 Eikelboom John W JW Connolly Stuart J SJ eng Editorial Comment 2012 05 02 United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Platelet Aggregation Inhibitors 5Q7ZVV76EI Warfarin R16CO5Y76E Aspirin AIM IM N Engl J Med. 2012 May 17;366(20):1859-69 22551105 Anticoagulants therapeutic use (...) Aspirin therapeutic use Female Heart Failure drug therapy Humans Male Platelet Aggregation Inhibitors therapeutic use Warfarin therapeutic use 2012 5 4 6 0 2012 5 4 6 0 2012 5 25 6 0 ppublish 22551103 10.1056/NEJMe1202504

2012 NEJM

119. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis

Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

120. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Pink J, Lane S, Pirmohamed M, Hughes DA Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of dabigatran etexilate and warfarin in patients with non-valvular atrial fibrillation and a moderate-to-high risk of stroke. Dabigatran 110mg

2012 NHS Economic Evaluation Database.